A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

被引：19
|
作者：
Cortes, Jorge E. [1 ]
Heidel, Florian H. [2 ,3 ]
Heuser, Michael [4 ]
Fiedler, Walter [5 ,6 ]
Smith, B. Douglas [7 ]
Robak, Tadeusz [8 ,9 ]
Fernandez, Pau Montesinos [10 ]
Ma, Weidong Wendy [11 ]
Shaik, M. Naveed [12 ]
Zeremski, Mirjana [12 ]
O'Connell, Ashleigh [13 ]
Chan, Geoffrey [13 ]
机构：
[1] Univ Texas M Anderson Canc Ctr, Houston, TX USA
[2] Otto Guericke Univ Med Ctr, Dept Hematol, Ctr Internal Med, Magdeburg, Germany
[3] Otto Guericke Univ Med Ctr, Dept Oncol, Ctr Internal Med, Magdeburg, Germany
[4] Hannover Med Sch, Hannover, Germany
[5] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Oncol, Hamburg, Germany
[6] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol, Hamburg, Germany
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Med Univ Lodz, Dept Hematol, Lodz, Poland
[9] Copernicus Mem Hosp, Lodz, Poland
[10] Hosp Univ Fe, Valencia, Spain
[11] Pfizer Oncol, New York, NY USA
[12] Pfizer Oncol, La Jolla, CA USA
[13] Pfizer Oncol, Collegeville, PA USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.99.99
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
99
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Andreef, Michael
    Faderl, Stefan
    Wright, John J.
    Zhang, Weiguo
    Konopleva, Marina
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 272A - 273A
  • [32] Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≤ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MOS).
    Faderl, S
    Gandhi, V
    Giles, F
    Estey, E
    Garcia-Manero, G
    O'Brien, S
    Wierda, W
    Kwari, M
    Craig, A
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 584S - 584S
  • [33] A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Stem Cell Transplantation
    Gutman, Jonathan A.
    Denoncourt, Emily
    Schatz, Derek
    Smith, Clayton
    Pollyea, Daniel Aaron
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S286 - S286
  • [34] SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
    Forsythe, A.
    Arondekar, B.
    Tremblay, G.
    Chan, G.
    Su, Y.
    VALUE IN HEALTH, 2017, 20 (09) : A415 - A415
  • [35] SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
    Forsythe, A.
    Arondekar, B.
    Tremblay, G.
    Chan, G.
    Su, Y.
    HAEMATOLOGICA, 2017, 102 : 380 - 380
  • [36] Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
    Kadia, Tapan M.
    Ravandi, Farhad
    Molica, Matteo
    Bataller, Alex
    Borthakur, Gautam
    Daver, Naval
    Jabbour, Elias
    Dinardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Ferrajoli, Alessandra
    Ylimaz, Musa
    Bose, Prithviraj
    Tidwell, Rebecca Slack
    Marx, Kayleigh R.
    Rausch, Caitlin R.
    Kanagal-Shamanna, Rashmi
    Wang, Sa
    Islam, Rabiul
    Champlin, Richard
    Shpall, Elizabeth
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1711 - 1720
  • [37] Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline
    Fukushima, Toshihiro
    Kawabata, Hiroshi
    Sawaki, Toshioki
    Satoh, Tomomi
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Sakai, Tomoyuki
    Miki, Miyuki
    Fujita, Yoshimasa
    Tanaka, Masao
    Kawanami, Takafumi
    Masaki, Yasufumi
    Okazaki, Toshiro
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2012, 32 (04) : 1347 - 1353
  • [38] A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study
    Buckley, Sarah A.
    Percival, Mary-Elizabeth
    Othus, Megan
    Halpern, Anna B.
    Huebner, Emily M.
    Becker, Pamela S.
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland B.
    Estey, Elihu H.
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1023 - 1029
  • [39] Idarubicin, high dose etoposide and high dose Ara-C (IDEA) treatment of high risk acute leukemia: A randomized study of schedule dependency of etoposide
    Johnston, L
    Damon, L
    Ries, C
    Rugo, H
    Linker, C
    BLOOD, 1996, 88 (10) : 855 - 855
  • [40] A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study
    Buckley, Sarah A.
    Percival, Mary-Elizabeth M.
    Othus, Megan
    Halpern, Anna B.
    Huebner, Emily M.
    Shaw, Carole
    Hendrie, Paul C.
    Shadman, Mazyar
    Becker, Pamela S.
    Walter, Roland B.
    Estey, Elihu H.
    BLOOD, 2016, 128 (22)
12345